Skip to content
MS
PW-039 Lipid Metabolism Anabolic (signalling) unreviewed

Eicosanoid Synthesis

Arachidonic acid (from membrane phospholipid) Prostaglandins, thromboxanes, prostacyclin, leukotrienes
Compartment
Cytosol / ER / nuclear membrane
Main tissue
Platelets, endothelium, leukocytes, most tissues
Rate-limiting
Phospholipase A2; Cyclooxygenase (COX-1 / COX-2; PTGS1/2)
Steps
5

Reaction steps

In source order, 5 total

showing 1–5
  1. 1

    Membrane phospholipid -> arachidonic acid + lysophospholipid

    Phospholipase A2 3.1.1.4 ST-0315 Irreversible/directional rate-limiting Ca2+
    Notes

    Rate-limiting release of the 20:4 omega-6 precursor. Corticosteroids suppress this step.

  2. 2

    Arachidonic acid + 2 O2 -> PGG2 -> PGH2

    Notes

    Bifunctional cyclooxygenase + peroxidase. Irreversibly acetylated by aspirin; reversibly inhibited by other NSAIDs; COX-2 selectively inhibited by coxibs.

  3. 3

    PGH2 -> PGE2 / PGD2 / PGF2alpha / PGI2 / TXA2

    Notes

    Endothelium favours PGI2 (vasodilator, antiaggregatory); platelets favour TXA2 (vasoconstrictor, proaggregatory) - the basis of low-dose aspirin cardioprotection.

  4. 4

    Arachidonic acid + O2 -> 5-HPETE -> LTA4

    5-Lipoxygenase (ALOX5) + FLAP 1.13.11.34 ST-0318 Irreversible/directional O2 Fe
    Notes

    Branch point of the leukotriene arm; zileuton inhibits 5-LOX.

  5. 5

    LTA4 -> LTB4, or LTA4 + glutathione -> LTC4 -> LTD4 -> LTE4

    Notes

    LTB4 is a neutrophil chemoattractant; the cysteinyl leukotrienes are the slow-reacting substance of anaphylaxis and are blocked at the receptor by montelukast/zafirlukast.

Showing all 5 steps.

Recent literature

Live Europe PMC search

Europe PMC · from cache · sorted by publication date

  1. 1
    Gut microbiota in chronic inflammation: the interplay with lipid mediators.

    Bao S, Yao C. · 2026-05-06

    open access unreviewed
  2. 2
    MicroRNA expression profiles in abdominal aortic aneurysms: A systematic review of potential diagnostic and prognostic biomarkers.

    Eini P, Eini P, Serpoush H, Rezayee M, Tremblay J. · 2026-05-07

    open access unreviewed
  3. 3
  4. 4
    Identification of age-related biomarkers for meat quality in Kangle chickens using multi-omics.

    He Q, Shang H, Wang Z, Xiong L, Lai X, Yi C, Xiong X. · 2026-05-23

    open access unreviewed
  5. 5
    Distinct Roles of Myeloid- and Hepatocyte-PLA2G6 Deletion in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.

    Li G, Staffer S, Tuma-Kellner S, Merle U, Chamulitrat W. · 2026-06-01

    open access unreviewed
  6. 6
    Higher Serum Omega-3 Polyunsaturated Fatty Acid Content Is Associated with Improved Long-Term Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease.

    Sikorska-Wiśniewska M, Mika A, Śledziński T, Kuźmiuk-Glembin I, Dębska-Ślizień A, Chmielewski M. · 2026-05-30

    open access unreviewed
  7. 7
    Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.

    Antal G, Pașcalău NA, Atyim E, Bătrîna O, Șoica C, Mioc M, Tandafirescu C, Mioc A. · 2026-05-27

    open access unreviewed
  8. 8
    The Pivotal Role of Plant Derivatives and Eicosanoid Signaling Modulation in Counteracting Cardiomiopathy.

    Ussia S, Ritorto G, Macrì R, Serra M, Tavernese A, Altomare C, Dardano DM, Idone C, Palma E, Muscoli C, Volte… · 2026-05-28

    open access unreviewed
  9. 9
    Nutraceutical Interventions in Stunting: Advances, Challenges, and Prospects.

    Rahimah S, Tallei TE, Savitri M, Yamada C, Kim HJ, Choi M, Park MN, Ophinni Y, Kim B. · 2026-05-20

    open access unreviewed
  10. 10
    Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020-2026).

    Jurek JM, Zablocka-Slowinska K, Pieczynska J, Lipert A, Clavero-Mestres H, Auguet T. · 2026-05-08

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.